#BEGIN_DRUGCARD DB00811

# AHFS_Codes:
08:18.32

# ATC_Codes:
J05AB04

# Absorption:
Rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averages 64%.

# Biotransformation:
Hepatic. Results of <i>in vitro</i> studies using both human and rat liver microsome preparations indicated little or no cytochrome P450 enzyme-mediated metabolism of ribavirin, with minimal potential for P450 enzyme-based drug interactions. Ribavirin has two pathways of metabolism: (1) a reversible phosphorylation pathway in nucleated cells; and (2) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxylic acid metabolite.

# Brand_Mixtures:
Rebetron (Schering-Plough) (Ribavirin + Interferon alpha)

# Brand_Names:
Copegus
RIBAV
RTC
RTCA
Rebetol
Rebetron
Rebretron
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribavirin Capsules
Ribavirin-TP
Tribavirin
Varazid
Vilona
Viramid
Virazid
Virazole

# CAS_Registry_Number:
36791-04-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H12N4O5

# Chemical_IUPAC_Name:
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]

# Dosage_Forms:
Aerosol	Respiratory (inhalation)

# Drug_Category:
Antimetabolites
Antiviral Agents

# Drug_Interactions:
Abacavir	Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.
Zalcitabine	Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. MOnitor for lactic acidosis during concomitant therapy.
Zidovudine	Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia.

# Drug_Reference:
16087250	Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005 Oct;68(1):10-7.
16123681	Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52.
16970600	Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006 Oct;13(10):683-9.
4340949	Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(50):705-6.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.85

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
142 mg/mL (max, at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ribavirin

# HET_ID:
RTP

# Half_Life:
9.5 hours

# InChI_Identifier:
InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1

# InChI_Key:
InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N

# Indication:
For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00423

# LIMS_Drug_ID:
811

# Mechanism_Of_Action:
Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral) and can be incorporated into RNA in RNA viral species.. Guanylyltranserase inhibition stops the capping of mRNA. These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.

# Melting_Point:
174-176 °C

# Molecular_Weight_Avg:
244.2047

# Molecular_Weight_Mono:
244.080769514

# Organisms_Affected:
Hepatitis C virus, RSV and other RNA/DNA viruses

# PDB_Experimental_ID:
1BX4

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451241

# Pharmacology:
Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease.

# Predicted_LogP_Hydrophobicity:
-1.9

# Predicted_LogS:
-0.87

# Predicted_Water_Solubility:
3.32e+01 g/l

# Primary_Accession_No:
DB00811

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
37542

# PubChem_Substance_ID:
46505883

# RxList_Link:
www.rxlist.com/cgi/generic2/ribavirin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00081

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
RBV
Ribavirina [INN-Spanish]
Ribavirine [INN-French]
Ribavirinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include "flu-like" symptoms, such as headache, fatigue, myalgia, and fever. The LD<sub>50</sub> in mice is 2 g/kg orally and is associated with hypoactivity and gastrointestinal symptoms (estimated human equivalent dose of 0.17 g/kg, based on body surface area conversion).

# Update_Date:
2013-02-08 16:19:39 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ribavirin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
ADK

# Phase_1_Metabolizing_Enzyme_1_ID:
6021

# Phase_1_Metabolizing_Enzyme_1_Name:
Adenosine kinase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Adenosine kinase
MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAED
KHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKA
AEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKAR
VCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGN
ETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFA
VLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPD
FH

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P55263

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16152757	McHutchison JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC Jr, McNair L, Ette E, Moseley S, Alam J: A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther. 2005;10(5):635-43.
16293677	Gish RG: Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13. Epub 2005 Nov 17.
16421290	Leyssen P, De Clercq E, Neyts J: The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol. 2006 Apr;69(4):1461-7. Epub 2006 Jan 18.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
IMPDH1

# Drug_Target_1_GenBank_ID_Gene:
J05272

# Drug_Target_1_GenBank_ID_Protein:
307067

# Drug_Target_1_GeneCard_ID:
IMPDH1

# Drug_Target_1_Gene_Name:
IMPDH1

# Drug_Target_1_Gene_Sequence:
>1545 bp
ATGGCGGACTACCTGATCAGCGGCGGCACCGGCTACGTGCCCGAGGATGGGCTCACCGCG
CAGCAGCTCTTCGCCAGCGCCGACGACCTCACCTACAACGACTTCCTGATTCTCCCAGGA
TTCATAGACTTCATAGCTGATGAGGTGGACCTGACCTCAGCCCTGACCCGGAAGATCACG
CTGAAGACGCCACTCATCTCCTCCCCCATGGACACTGTGACAGAGGCTGACATGGCCATT
GCCATGGCTCTGATGGGAGGTATTGGGTTCATTCACCACAACTGCACCCCAGAGTTCCAG
GCCAATGAAGTACGCAAGGTCAAGAACTTTGAACAGGGCTTCATCACGGACCCTGTGGTG
CTGAGCCCCTCGCACACTGTGGGCGATGTGCTGGAGGCCAAGATGCGGCATGGCTTCTCT
GGCATCCCCATCACTGAGACGGGCACCATGGGCAGCAAGCTGGTGGGCATCGTCACCTCC
CGAGACATCGACTTTCTTGCTGAGAAGGACCACACCACCCTCCTCAGTGAGGTGATGACG
CCAAGGATTGAACTGGTGGTGGCTCCAGCAGGTGTGACGTTGAAAGAGGCAAATGAGATC
CTGCAGCGTAGCAAGAAAGGGAAGCTGCCTATCGTCAATGATTGCGATGAGCTGGTGGCC
ATCATCGCCCGCACCGACCTGAAGAAGAATCGAGACTACCCTCTGGCCTCCAAGGATTCC
CAGAAGCAGCTGCTCTGTGGGGCAGCTGTGGGCACCCGTGAGGATGACAAATACCGTCTG
GACCTGCTGACCCAGGCGGGGGTCGACGTCATAGTCTTCCACTCGTCCCAAGGGAATTCG
GTGTATCAGATCGCCATGGTGCATTACATCAAACAGAAGTACCCCCACCTCCAGGTGATT
GGGGGGAACGTGGTGACAGCAGCCCAGGCCAAGAACCTGATTGATGCTGGTGTGGACGGG
CTGCGCGTGGGCATGGGCTGCGGCTCCATCTGCATCACCCAGGAAGTGATGGCCTGTGGT
CGGCCCCAGGGCACTGCTGTGTACAAGGTGGCTGAGTATGCCCGGCGCTTTGGTGTGCCC
ATCATAGCCGATGGCGGCATCCAGACCGTGGGACACGTGGTCAAGGCCCTGGCCCTTGGA
GCCTCCACAGTGATGATGGGCTCCCTGCTGGCCGCCACTACGGAGGCCCCTGGCGAGTAC
TTCTTCTCAGACGGGGTGCGGCTCAAGAAGTACCGGGGCATGGGCTCACTGGATCCCATG
GAGAAGAGCAGCAGCAGCCAGAAACGATACTTCAGCGAGGGGGATAAAGTGAAGATCGCA
CAGGGTGTCTCGGGCTCCATCCAGGACAAAGGATCCATTCAGAAGTTCGTGCCCTACCTC
ATAGCAGGCATCCAACACGGCTGCCAGGATATCGGGGCCCGCAGCCTGTCTGTCCTTCGG
TCCATGATGTACTCAGGAGAGCTCAAGTTTGAGAAGCGGACCATGTCGCCCCAGATTGAG
GGTGGTGTCCATGGCCTGCACTCTTACGAAAAGCGGCTGTACTGA

# Drug_Target_1_General_Function:
Nucleotide transport and metabolism

# Drug_Target_1_General_References:
11875049	Kennan A, Aherne A, Palfi A, Humphries M, McKee A, Stitt A, Simpson DA, Demtroder K, Orntoft T, Ayuso C, Kenna PF, Farrar GJ, Humphries P: Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum Mol Genet. 2002 Mar 1;11(5):547-57.
11875050	Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Daiger SP: Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet. 2002 Mar 1;11(5):559-68.
1969416	Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990 Mar 25;265(9):5292-5.
7763314	Hager PW, Collart FR, Huberman E, Mitchell BS: Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol. 1995 May 11;49(9):1323-9.

# Drug_Target_1_HGNC_ID:
HGNC:6052

# Drug_Target_1_HPRD_ID:
08853

# Drug_Target_1_ID:
838

# Drug_Target_1_Locus:
7q31.3-q32

# Drug_Target_1_Molecular_Weight:
55407

# Drug_Target_1_Name:
Inosine-5'-monophosphate dehydrogenase 1

# Drug_Target_1_Number_of_Residues:
514

# Drug_Target_1_PDB_ID:
1JCN

# Drug_Target_1_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Thioguanine Pathway	SMP00430

# Drug_Target_1_Pfam_Domain_Function:
PF00478	IMPDH
PF00571	CBS

# Drug_Target_1_Protein_Sequence:
>Inosine-5'-monophosphate dehydrogenase 1
MADYLISGGTGYVPEDGLTAQQLFASADGLTYNDFLILPGFIDFIADEVDLTSALTRKIT
LKTPLISSPMDTVTEADMAIAMALMGGIGFIHHNCTPEFQANEVRKVKKFEQGFITDPVV
LSPSHTVGDVLEAKMRHGFSGIPITETGTMGSKLVGIVTSRDIDFLAEKDHTTLLSEVMT
PRIELVVAPAGVTLKEANEILQRSKKGKLPIVNDCDELVAIIARTDLKKNRDYPLASKDS
QKQLLCGAAVGTREDDKYRLDLLTQAGVDVIVLDSSQGNSVYQIAMVHYIKQKYPHLQVI
GGNVVTAAQAKNLIDAGVDGLRVGMGCGSICITQEVMACGRPQGTAVYKVAEYARRFGVP
IIADGGIQTVGHVVKALALGASTVMMGSLLAATTEAPGEYFFSDGVRLKKYRGMGSLDAM
EKSSSSQKRYFSEGDKVKIAQGVSGSIQDKGSIQKFVPYLIAGIQHGCQDIGARSLSVLR
SMMYSGELKFEKRTMSAQIEGGVHGLHSYEKRLY

# Drug_Target_1_Reaction:
inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Rate limiting enzyme in the de novo synthesis of guanine nucleotides and therefore is involved in the regulation of cell growth. It may also have a role in the development of malignancy and the growth progression of some tumors

# Drug_Target_1_SwissProt_ID:
P20839

# Drug_Target_1_SwissProt_Name:
IMDH1_HUMAN

# Drug_Target_1_Synonyms:
EC 1.1.1.205
IMP dehydrogenase 1
IMPD 1
IMPDH-I

# Drug_Target_1_Theoretical_pI:
6.90

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
1

# Drug_Target_2_Drug_References:
15917509	Wu JZ, Larson G, Walker H, Shim JH, Hong Z: Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother. 2005 Jun;49(6):2164-71.
17379518	Kumarapperuma SC, Sun Y, Jeselnik M, Chung K, Parker WB, Jonsson CB, Arterburn JB: Structural effects on the phosphorylation of 3-substituted 1-beta-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3203-7. Epub 2007 Mar 12.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U50196

# Drug_Target_2_GenBank_ID_Protein:
1224125

# Drug_Target_2_GeneCard_ID:
ADK

# Drug_Target_2_Gene_Name:
ADK

# Drug_Target_2_Gene_Sequence:
>1038 bp
ATGACGTCAGTCAGAGAAAATATTCTCTTTGGAATGGGAAATCCTCTGCTTGACATCTCT
GCTGTAGTGGACAAAGATTTCCTTGATAAGTATTCTCTGAAACCAAATGACCAAATCTTG
GCTGAAGACAAACACAAGGAACTGTTTGATGAACTTGTGAAAAAATTCAAAGTCGAATAT
CATGCTGGTGGCTCTACCCAGAATTCAATTAAAGTGGCTCAGTGGATGATTCAACAGCCA
CACAAAGCAGCAACATTTTTTGGATGCATTGGGATAGATAAATTTGGGGAGATCCTGAAG
AGAAAAGCTGCTGAAGCCCATGTGGATGCTCATTACTACGAGCAGAATGAGCAGCCAACA
GGAACTTGTGCTGCATGCATCACTGGTGACAACAGGTCCCTCATAGCTAATCTTGCTGCT
GCCAATTGTTATAAAAAGGAAAAACATCTTGATCTGGAGAAAAACTGGATGTTGGTAGAA
AAAGCAAGAGTTTGTTATATAGCAGGCTTTTTTCTTCACGTTTCCCCAGAGTCAGTATTA
AAGGTGGCTCACCATGCTTCTGAAAACAACAGGATTTTCACTTTGAATCTATCTGCACCG
TTTATTAGCCAGTTCTACAAGGAATCATTGATGAAAGTTATGCCTTATGTTGATATACTT
TTTGGAAATGAGACAGAAGCTGCCACTTTTGCTAGAGAGCAAGGCTTTGAGACTAAAGAC
ATTAAAGAGATAGCCAAAAAGACACAAGCCCTGCCAAAGATGAACTCAAAGAGGCAGCGA
ATCGTGATCTTCACCCAAGGGAGAGATGACACTATAATGGCTACAGAAAGTGAAGTCACT
GCTTTTGCTGTCTTGGATCAAGACCAGAAAGAAATTATTGATACCAATGGAGCTGGAGAT
GCATTTGTTGGAGGTTTTCTGTCTCAACTGGTCTCTGACAAGCCTCTGACTGAATGTATC
CGTGCTGGCCACTATGCAGCAAGCATCATAATTAGACGGACTGGCTGCACCTTTCCTGAG
AAGCCAGACTTCCACTGA

# Drug_Target_2_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_2_General_References:
12112843	Maguire PB, Wynne KJ, Harney DF, O'Donoghue NM, Stephens G, Fitzgerald DJ: Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics. 2002 Jun;2(6):642-8.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
8577746	Spychala J, Datta NS, Takabayashi K, Datta M, Fox IH, Gribbin T, Mitchell BS: Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1232-7.
8917457	Singh B, Hao W, Wu Z, Eigl B, Gupta RS: Cloning and characterization of cDNA for adenosine kinase from mammalian (Chinese hamster, mouse, human and rat) species. High frequency mutants of Chinese hamster ovary cells involve structural alterations in the gene. Eur J Biochem. 1996 Oct 15;241(2):564-71.
9070863	McNally T, Helfrich RJ, Cowart M, Dorwin SA, Meuth JL, Idler KB, Klute KA, Simmer RL, Kowaluk EA, Halbert DN: Cloning and expression of the adenosine kinase gene from rat and human tissues. Biochem Biophys Res Commun. 1997 Feb 24;231(3):645-50.
9843365	Mathews II, Erion MD, Ealick SE: Structure of human adenosine kinase at 1.5 A resolution. Biochemistry. 1998 Nov 10;37(45):15607-20.

# Drug_Target_2_HGNC_ID:
GNC:257

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6021

# Drug_Target_2_Locus:
10q22|10q11-q24

# Drug_Target_2_Molecular_Weight:
40545.1

# Drug_Target_2_Name:
Adenosine kinase

# Drug_Target_2_Number_of_Residues:
362

# Drug_Target_2_PDB_ID:
1BX4

# Drug_Target_2_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Thioguanine Pathway	SMP00430

# Drug_Target_2_Pfam_Domain_Function:
PF00294	PfkB

# Drug_Target_2_Protein_Sequence:
>Adenosine kinase
MAAAEEEPKPKKLKVEAPQALRENILFGMGNPLLDISAVVDKDFLDKYSLKPNDQILAED
KHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKAATFFGCIGIDKFGEILKRKA
AEAHVDAHYYEQNEQPTGTCAACITGDNRSLIANLAAANCYKKEKHLDLEKNWMLVEKAR
VCYIAGFFLTVSPESVLKVAHHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGN
ETEAATFAREQGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFA
VLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRRTGCTFPEKPD
FH

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides

# Drug_Target_2_SwissProt_ID:
P55263

# Drug_Target_2_SwissProt_Name:
ADK_HUMAN

# Drug_Target_2_Synonyms:
AK
Adenosine 5'-phosphotransferase

# Drug_Target_2_Theoretical_pI:
6.67

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X57559

# Drug_Target_3_GenBank_ID_Protein:
61991

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
L

# Drug_Target_3_Gene_Sequence:
>6789 bp
ATGGCGGCCTCTTCTGAGATACTCCTTCCTGAAGTCCACTTGAACTCACCAATAGTCAAA
CACAAACTCATATACTACTTATTACTAGGGCACTTCCCGCATGATCTTGACATTTCTGAA
ATAAGCCCCCTTCACAATAATGATTGGGATCAAATTGCCAGAGAAGAATCCAATCTTGCT
GAACGACTTGGAGTAGCTAAATCTGAATTAATTAAACGTGTGCCCGCATTTAGAGCAACT
AGATGGCGTAGTCATGCAGCCGTCCTTATATGGCCTTCTTGTATACCATTTCTTGTTAAA
TTCCTACCTCATTCTAAGCTTCAACCAGTAGAACAATGGTACAAGTTGATCAATGCTTCA
TGTAATACTATATCTGACTCAATTGATAGATGTATGGAGAATATTTCTATTAAGCTTACT
GGGAAAAACAATCTATTCTCTCGATCCAGAGGAACTGCAGGTGCAGGTAAAAACAGTAAA
ATCACCCTCAATGATATCCAATCTATTTGGGAATCAAACAAGTGGCAACCTAATGTATCT
TTATGGCTTACAATTAAATACCAAATGCGACAACTTATAATGCATCAAAGTTCTCGTCAG
CCGACTGATTTAGTTCACATTGTTGACACACGATCTGGTCTAATAGTTATCACCCCTGAA
CTTGTTATTTGTTTTGATCGGTTAAATAGTGTTTTAATGTATTTTACATTTGAGATGACT
TTAATGGTAAGTGACATGTTTGAGGGAAGGATGAATGTCACCGCTCTCTGCACTATTAGT
CATTACTTATCTCCACTAGGGCCAAGGATAGATAGATTGTTTTCCATTGTAGATGAATTA
GCACAACTATTAGGTGACACTGTATATAAAGTTATTGCATCTCTTGAATCTTTAGTATAT
GGGTGTCTACAACTTAAAGATCCAGTAGTGGAATTAGCAGGGTCATTTCATTCCTTTATT
ACACAAGAGATTATAGATATCCTAATTGGTTCAAAAGCCCTTGATAAGGATGAATCAATA
ACTGTTACTACACAATTGTTAGATATATTTTCCAACCTTTCTCCAGATTTAATTGCTGAG
ATGTTGTGTCTCATGAGACTTTGGGGTCATCCCACTCTTACTGCTGCGCAAGTGGGTAAA
GTGAGAGAATCTATGTGTGCAGGTAAGTTACTTGATTTCCCTACAATAATGAAAACTCTT
GCTTTTTTCCACACAATTTTAATTAATGGTTACCGTAGAAAGAAAAATGGAATGTGGCCT
CCACTTATACTTCCTAAAAATGCATCAAAAAGCTTAATAGAATTTCAACATGATAATGCT
GAAATATCTTACGAATATACACTCAAGCATTGGAAAGAGATATCTCTCATAGAATTTAGA
AAGTGCTTTGACTTTGATCCTGGTGAGGAGCTAAGCATTTTTATGAAAGACAAGGCAATA
AGTGCTCCAAGAAGTGATTGGATGAGTGTATTTCGTAGAAGTCTAATAAAACAACGACAT
CAGAGACATCATATTCCTATGCCCAATCCATTTAATAGACGTCTATTACTCAATTTCTTA
GAAGATGACAGTTTTGATCCAGTTGCCGAGCTTCGATATGTTACCGGTGGTGAATATCTC
CAAGATGACACATTTTGTGCATCTTACTCATTAAAAGAGAAAGAAATAAAACCAGATGGA
AGGATATTTGCTAAGCTTACTAATAGAATGCGGTCCTGTCAAGTAATTGCGGAAGCAATT
CTCGCAAATCATGCAGGTACTCTAATGAAGGAAAACGGAGTTGTCTTGAATCAATTATCA
CTGACTAAATCATTGCTTACTATGAGTCAAATTGGCATAATATCAGAAAAGGCGAAGAGA
TATACGCGAGATAACATCTCATCCCAAGGTTTCCATACAATCAAGACTGATTCTAAAAAT
AAGAGGAAAAGCAAAACTGCATCATCATACCTCACAGATCCTGATGATACATTTGAACTT
AGTGCATGTTTTATAACTACTGATCTTGCTAAATACTGTCTTCAATGGAGATATCAGACC
ATAATCCATTTTGCTCGAACATTAAACAGAATGTATGGAGTTCCACATTTATTTGAATGG
ATTCATCTTCGTTTAATTAGATCTACATTATATGTTGGTGATCCATTCAATCCTCCTGCC
GCAACTGATGCTTTCGATCTAGATAAAGTATTAAATGGTGATATCTTTATAGTCTCCAAG
GGAGGTATTGAAGGCCTATGTCAGAAAATGTGGACAATGATCTCTATTTCTGTGATCATC
CTCTCTTCAGCCGAATCCAAAACAAGAGTAATGAGCATGGTTCAAGGAGATAATCAGGCG
ATTGCAGTTACAACAAGAGTTCCTAGATCATTACCTAGTATTCAGAAAAAGGAGTTAGCC
TATGCAGCAAGCAAGTTATTTTTTGAAAGACTTAGGGCAAATAATTATGGGTTGGGTCAT
CAGCTAAAGGCTCAAGAAACTATAATAAGTTCCACGTTCTTCATATATAGTAAACGGGTA
TTTTATCAAGGACGTATACTAACACAGGCACTCAAAAATGCTAGCAAGTTATGTCTTACT
GCAGATGTATTAGGTGAATGTACTCAAGCTTCCTGTTCAAATTCTGCTACTACCATCATG
AGATTAACAGAAAATGGGGTTGAGAAAGATACATGTTATAAGCTTAATATTTATCAGTCC
ATTCGTCAACTCACATATGATCTAATATTTCCCCAATACTCCATACCAGGTGAAACTATA
AGTGAGATTTTCCTACAGCATCCAAGACTAATCTCACGTATTGTTCTGCTCCCTTCACAG
CTAGGTGGTCTTAATTACCTCGCATGTAGCAGATTATTTAACCGCAATATCGGAGATCCT
CTTGGTACAGCTGTGGCAGATCTCAAGAGGTTAATTAAATGTGGTGCTCTTGAATCATGG
ATACTGTATAATTTACTAGCAAGAAAACCAGGGAAAGGTTCATGGGCAACTTTAGCAGCC
GATCCATACTCATTGAATCAAGAATATCTTTATCCTCCTACTACTATACTTAAAAGACAT
ACTCAAAATACTTTAATGGAGATATGTCGGAATCCTATGTTAAAGGGAGTTTTTACAGAT
AATGCAAAAGAGGAGGAAAATCTCCTTGCAAAATTTCTTCTTGATCGTGATATAGTATTG
CCAAGAGTTGCACACATTATAATAGATCAATCTAGCATCGGAAGGAAGAAACAGATACAA
GGATTTTTTGACACCACAAGGACCATAATGAGACGATCATTTGAAATCAAACCACTCTCA
ACTAAGAAGACTCTTTCAGTCATAGAATATAATACTAATTACTTATCTTATAACTACCCT
GTCATACTTAATCCTTTACCTATTCCTGGATATTTAAATTATATTACTGACCAAACTTGC
AGTATTGATATATCTAGAAGTTTAAGAAAATTATCATGGTCTTCTTTATTGAATGGAAGA
ACTTTAGAAGGATTAGAAACTCCAGATCCAATTGAAGTTGTCAATGGTTTCTTGATTGTA
GGTACAGGAGATTGTGATTTTTGTATGCAGGGTGACGACAAATTTACTTGGTTCTTTTTA
CCTATGGGGATAATTATTGATGGAAATCCTGAAACTAATCCACCCATCAGAGTTCCATAC
ATTGGGTCTAGAACAGAGGAAAGAAGAGTTGCATCAATGGCATATATTAAAGGTGCCACA
CACAGTTTGAAGGCTGCTCTTAGAGGCGCAGGGGTATATATTTGGGCATTCGGGGATACT
GTAGTGAACTGGAATGATGCACTTGATATCGCAAATACTAGGGTTAAGATATCCCTAGAG
CAACTTCAGACCCTTACACCTCTTCCTACATCTGCAAACATTACACACCGTTTAGATGAT
GGAGCCACAACACTTAAATTCACTCCAGCTAGTTCCTATGCATTTTCTAGTTATACTCAT
ATATCAAATGATCAACAATATTTAGAAATAGATCAGAGAGTAGTCGATTCTAATATTATT
TATCAACAATTAATGATAACAGGACTTGGGATTATTGAGACCTACCATAACCCACCTATA
AGGACTTCTACACAAGAAATCACTCTCCATTTGCACACTAGCTCATCTTGTTGTGTTAGA
AGTGTAGATGGTTGCCTTATATGTGAGAGCAATGGAGAGGTTCCTCAGATCACTGTTCCC
TATACTAATACATTTGTATATGATCCTGATCCACTAGCAGATTATGAGATTGCACACCTA
GATTATCTCTCCTACCAAGCTAAAATTGGAAGTACAGATTACTACTCACTCACTGATAAA
ATTGACCTATTAGCACATTTAACTGCAAAACAAATGATAAACTCAATAATTGGGTTAGAT
GAAACAGTATCAATTGTCAATGATGCGGTTATCCTATCTGACTATACTAATAACTGGATT
AGTGAATGTTCTTATACTAAGATAGATTTAGTTTTTAAATTAATGGCATGGAATTTCCTT
CTTGAGCTTGCATTCCAGATGTACTACTTAAGGATATCATCTTGGACAAATATATTTGAC
TATACTTATATGACTTTGCGCAGGATACCCGGAACTGCTCTAAATAATATTGCAGCTACT
ATTAGCCATCCAAAATTATTAAGACGTGCAATGAATCTTGATATTATCACTCCTATACAT
GCACCGTATTTAGCTTCATTAGATTATGTCAAATTAAGTATTGATGCAATTCAGTGGGGA
GTTAAACAAGTTCTTGCTGATTTATCAAATGGAATTGATCTTGAAATCTTGATTCTTTCA
GAGGATTCAATGGAAATTAGTGATAGGGCAATGAATCTCATTGCTAGAAAACTAACTCTC
CTTGCACTTGTTAAAGGTGAGAACTATACTTTTCCAAAAATTAAAGGGATGCCACCAGAA
GAAAAGTGTTTAGTCTTAACTGAATATCTAGCAATGTGTTATCAAAATACTCATCACTTA
GATCCAGATCTTCAAAAGTATTTATATAATCTAACTAATCCAAAATTGACTGCATTTCCC
AGTAACAACTTCTACTTAACTAGAAAAATCCTTAATCAAATTAGAGAATCAGACGAAGGA
CAATATATTATCACCTCATATTATGAATCCTTCGAACAATTAGAAACAGATATAATTCTT
CACTCTACTTTAACTGCTCCTTATGATAATTCAGAAAACTCTAACAAAGTTCGATTTATC
CCTTTCGACATCTTTCCACATCCAGAATCTCTCGAGAAATATCCTCTTCCAGTTGATCAT
GACTCTCAATCTGCAATTTCAACACTAATTCCAGGCCCTCCTTCTCATCATGTATTACGA
CCACTAGGAGTGTCATCCACAGCTTGGTATAAAGGGATAAGTTATTGTAGATACCTAGAA
ACACAAAAGATACAGACTGGTGATCATCTTTATTTAGCCGAAGGAAGCGGTGCTTCAATG
TCACTTCTAGAACTCTTATTTCCAGGAGATACTGTCTATTATAATAGTCTTTTTAGTAGT
GGAGAGAATCCTCCACAGAGAAACTATGCCCCTCTTCCAACTCAATTTGTACAGAGTGTT
CCATATAAATTGTGGCAAGCTGATCTTGCTGATGATAGCAATTTGATAAAAGATTTTGTC
CCATTATGGAATGGAAACGGTGCAGTTACAGACTTATCAACAAAGGATGCAGTTGCATTC
ATAATACATAAAGTAGGAGCAGAGAAAGCATCCCTTGTCCATATAGATCTCGAATCAACT
GCTAATATAAATCAGCAAACTCTGTCCAGATCCCAGATTCATTCATTAATTATAGCAACT
ACTGTTCTTAAGAGGGGTGGGATATTAATTTATAAAACATCATGGCTTCCGTTTTCTAGG
TTTAGTCAACTAGCAGGTCTACTTTGGTGCTTCTTTGACCGGATCCATCTAATACGTAGT
AGCTATTCTGATCCTCACAGTCATGAGGTTTATCTTGTATGTAGACTTGCCGCAGATTTT
AGAACTATCGGTTTCAGTGCAGCTCTAGTAACTGCTACTACTCTTCACAATGACGGATTC
ACAACAATACATCCTGATGTTGTTTGTAGTTATTGGCAACACCATCTTGAAAATGTTGGG
AGAGTCGGAAAAGTAATTGATGAGATACTTGATGGTTTAGCCACCAACTTCTTCGCAGGA
GATAATGGGCTTATTCTAAGATGTGGAGGAACTCCAAGCTCCAGAAAATGGTTAGAGATT
GACCAGTTAGCATCATTTGATTTGGTTCAAGATGCTCTGGTTACACTTATCACTATACAC
CTAAAGGAAATTATAGAAGTGCAGTCATCACATACAGAGGATTATACATCTCTCCTCTTC
ACACCTTATAATATTGGTGCAGCAGGGAAAGTCAGAACTATCATCAAATTAATTCTAGAA
CGATCTTTAATGTATACAGTCCGAAATTGGTTAGTTTTACCCAGTTCCATCCGGGATTCT
GTACGACAAGATTTAGAATTAGGGTCATTTAGATTAATGTCTATTTTAAGTGAACAGACA
TTTCTTAAAAAGACACCCACAAAAAAATACTTACTTGATCAGCTTACAAGGACATATATA
TCAACCTTCTTTAACTCTCACTCAGTCCTTCCCCTCCACCGTCCATATCAAAAACAAATA
TGGAAAGCCTTAGGTAGTGTAATATATTGTTCGGAGACAGTTGATATACCTCTAATTAAA
GACATTCAGATAGAAGATATTAATGATTTTGAAGATATCGAGAGGGGTATCGATGGCGAA
GAATTATGA

# Drug_Target_3_General_Function:
Involved in RNA binding

# Drug_Target_3_General_References:
1645865	Kawano M, Okamoto K, Bando H, Kondo K, Tsurudome M, Komada H, Nishio M, Ito Y: Characterizations of the human parainfluenza type 2 virus gene encoding the L protein and the intergenic sequences. Nucleic Acids Res. 1991 May 25;19(10):2739-46.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
752

# Drug_Target_3_Locus:
6p21.3

# Drug_Target_3_Molecular_Weight:
256386

# Drug_Target_3_Name:
Large structural protein

# Drug_Target_3_Number_of_Residues:
2262

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00946	Paramyx_RNA_pol

# Drug_Target_3_Protein_Sequence:
>Large structural protein
MAASSEILLPEVHLNSPIVKHKLIYYLLLGHFPHDLDISEISPLHNNDWDQIAREESNLA
ERLGVAKSELIKRVPAFRATRWRSHAAVLIWPSCIPFLVKFLPHSKLQPVEQWYKLINAS
CNTISDSIDRCMENISIKLTGKNNLFSRSRGTAGAGKNSKITLNDIQSIWESNKWQPNVS
LWLTIKYQMRQLIMHQSSRQPTDLVHIVDTRSGLIVITPELVICFDRLNSVLMYFTFEMT
LMVSDMFEGRMNVTALCTISHYLSPLGPRIDRLFSIVDELAQLLGDTVYKVIASLESLVY
GCLQLKDPVVELAGSFHSFITQEIIDILIGSKALDKDESITVTTQLLDIFSNLSPDLIAE
MLCLMRLWGHPTLTAAQVGKVRESMCAGKLLDFPTIMKTLAFFHTILINGYRRKKNGMWP
PLILPKNASKSLIEFQHDNAEISYEYTLKHWKEISLIEFRKCFDFDPGEELSIFMKDKAI
SAPRSDWMSVFRRSLIKQRHQRHHIPMPNPFNRRLLLNFLEDDSFDPVAELRYVTGGEYL
QDDTFCASYSLKEKEIKPDGRIFAKLTNRMRSCQVIAEAILANHAGTLMKENGVVLNQLS
LTKSLLTMSQIGIISEKAKRYTRDNISSQGFHTIKTDSKNKRKSKTASSYLTDPDDTFEL
SACFITTDLAKYCLQWRYQTIIHFARTLNRMYGVPHLFEWIHLRLIRSTLYVGDPFNPPA
ATDAFDLDKVLNGDIFIVSKGGIEGLCQKMWTMISISVIILSSAESKTRVMSMVQGDNQA
IAVTTRVPRSLPSIQKKELAYAASKLFFERLRANNYGLGHQLKAQETIISSTFFIYSKRV
FYQGRILTQALKNASKLCLTADVLGECTQASCSNSATTIMRLTENGVEKDTCYKLNIYQS
IRQLTYDLIFPQYSIPGETISEIFLQHPRLISRIVLLPSQLGGLNYLACSRLFNRNIGDP
LGTAVADLKRLIKCGALESWILYNLLARKPGKGSWATLAADPYSLNQEYLYPPTTILKRH
TQNTLMEICRNPMLKGVFTDNAKEEENLLAKFLLDRDIVLPRVAHIIIDQSSIGRKKQIQ
GFFDTTRTIMRRSFEIKPLSTKKTLSVIEYNTNYLSYNYPVILNPLPIPGYLNYITDQTC
SIDISRSLRKLSWSSLLNGRTLEGLETPDPIEVVNGFLIVGTGDCDFCMQGDDKFTWFFL
PMGIIIDGNPETNPPIRVPYIGSRTEERRVASMAYIKGATHSLKAALRGAGVYIWAFGDT
VVNWNDALDIANTRVKISLEQLQTLTPLPTSANITHRLDDGATTLKFTPASSYAFSSYTH
ISNDQQYLEIDQRVVDSNIIYQQLMITGLGIIETYHNPPIRTSTQEITLHLHTSSSCCVR
SVDGCLICESNGEVPQITVPYTNTFVYDPDPLADYEIAHLDYLSYQAKIGSTDYYSLTDK
IDLLAHLTAKQMINSIIGLDETVSIVNDAVILSDYTNNWISECSYTKIDLVFKLMAWNFL
LELAFQMYYLRISSWTNIFDYTYMTLRRIPGTALNNIAATISHPKLLRRAMNLDIITPIH
APYLASLDYVKLSIDAIQWGVKQVLADLSNGIDLEILILSEDSMEISDRAMNLIARKLTL
LALVKGENYTFPKIKGMPPEEKCLVLTEYLAMCYQNTHHLDPDLQKYLYNLTNPKLTAFP
SNNFYLTRKILNQIRESDEGQYIITSYYESFEQLETDIILHSTLTAPYDNSENSNKVRFI
PFDIFPHPESLEKYPLPVDHDSQSAISTLIPGPPSHHVLRPLGVSSTAWYKGISYCRYLE
TQKIQTGDHLYLAEGSGASMSLLELLFPGDTVYYNSLFSSGENPPQRNYAPLPTQFVQSV
PYKLWQADLADDSNLIKDFVPLWNGNGAVTDLSTKDAVAFIIHKVGAEKASLVHIDLEST
ANINQQTLSRSQIHSLIIATTVLKRGGILIYKTSWLPFSRFSQLAGLLWCFFDRIHLIRS
SYSDPHSHEVYLVCRLAADFRTIGFSAALVTATTLHNDGFTTIHPDVVCSYWQHHLENVG
RVGKVIDEILDGLATNFFAGDNGLILRCGGTPSSRKWLEIDQLASFDLVQDALVTLITIH
LKEIIEVQSSHTEDYTSLLFTPYNIGAAGKVRTIIKLILERSLMYTVRNWLVLPSSIRDS
VRQDLELGSFRLMSILSEQTFLKKTPTKKYLLDQLTRTYISTFFNSHSVLPLHRPYQKQI
WKALGSVIYCSETVDIPLIKDIQIEDINDFEDIERGIDGEEL

# Drug_Target_3_Reaction:
S-adenosyl-L-methionine + G(5')pppR-RNA = S-adenosyl-L-homocysteine + m7G(5')pppR-RNA (mRNA containing an N7-methylguanine cap)

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Displays RNA-directed RNA polymerase, mRNA guanylyl transferase, mRNA (guanine-7-N-)-methyltransferase and poly(A) synthetase activities. The viral mRNA guanylyl transferase displays a different biochemical reaction than the cellular enzyme. The template is composed of the viral RNA tightly encapsidated by the nucleoprotein (N). Functions either as transcriptase or as replicase. The transcriptase synthesizes subsequently the subgenomic RNAs, assuring their capping and polyadenylation by a stuttering mechanism. The transcriptase stutters on a specific sequence, resulting on a cotranscriptional editing of the phosphoprotein (P) mRNA. The replicase mode is dependent on intracellular N protein concentration. In this mode, the polymerase replicates the whole viral genome without recognizing the transcriptional signals

# Drug_Target_3_SwissProt_ID:
P26676

# Drug_Target_3_SwissProt_Name:
L_PI2HT

# Drug_Target_3_Synonyms:
Protein L
Replicase
Transcriptase

# Drug_Target_3_Theoretical_pI:
6.97

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
14563844	Bougie I, Bisaillon M: Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. J Biol Chem. 2003 Dec 26;278(52):52471-8. Epub 2003 Oct 16.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M25932

# Drug_Target_4_GenBank_ID_Protein:
324960

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
PB1

# Drug_Target_4_Gene_Sequence:
>2274 bp
ATGGATGTCAATCCGACCTTACTTTTCTTAAAAGTGCCAGCACAAAATGCTATAAGCACA
ACTTTCCCTTATACTGGAGACCCTCCTTACAGCCATGGGACAGGAACAGGGTACACCATG
GATACTGTCAACAGGACACATCAGTACTCAGAAAGGGGAAGATGGACAAAAAACACCGAA
ACTGGAGCACCACAGCTCAACCCAATTGATGGGCCACTACCAGAAGACAATGAACCAAGT
GGTTATGCCCAAACAGATTGTGTATTAGAAGCAATGGCTTTCCTTGAGGAATCCCATCCT
GGTATTTTTGAAAACTCATGTATTGAAACGATGGAGGTTGTTCAGCAAACACGAGTGGAC
AAGCTGACACAAGGCCGACAGACCTATGACTGGACTCTGAATAGAAACCAGCCTGCTGCT
ACAGCATTGGCAAACACAATAGAAGTGTTCAGATCAAATGGCCTCATGGCAAATGAATCC
GGAAGGCTAATAGACTTTCTTAAAGATGTAATGGAGTCAATGGACAAAGAAGAAATAGAG
ATCACAACCCATTTTCAGAGAAAGAGACGGGTGAGGGACAATGTGACTAAGAAAATGGTG
ACACAAAGAACAATAGGCAAAAAGAAACAGAGATTAAACAAAAGGAGTTATCTAATTAGG
GCATTGACCCTGAACACAATGACCAAAGATGCTGAGAGAGGGAAACTAAAACGAAGAGCA
ATTGCAACCCCAGGGATGCAAATAAGGGGGTTTGTATACTTTGTTGAGACACTGGCAAGA
AGTATATGTGAAAAACTTGAACAATCAGGACTGCCAGTTGGAGGAAATGAAAAGAAAGCA
AAGTTGGCAAATGTTGTAAGGAAGATGATGACCAATTCTCAGGACACTGAAATTTCTTTC
ACCATCACTGGAGACAACACCAAATGGAACGAAAATCAAAACCCTAGAATGTTTTTGGCC
GTGATCACATATATAACCAGAAATCAGCCCGAATGGTTCAGAAATATTCTAAGTATTGCT
CCAATAATGTTCTCAAACAAAATGGCGAGACTAGGTAAGGGTTACATGTTTGAGAGCAAG
AGTATGAAACTTAGAACTCAAATATCTGCAGAAATGCTAGCAAACATCGATTTGAAGTAT
TTCAATGATTCAACAAGAAAGAAAATTGAAAAAATCCGGCCGCTCTTAATAGATGGGACT
GCATCACTGAGCCCTGGAATGATGATGGGCATGTTCAATATGTTAAGCACTGTATTGGGC
GTTTCCATCCTGAATCTTGGACAAAAGAGATACACAAAGACTACTTACTGGTGGGATGGT
CTTCAATCATCTGATGATTTTGCTCTGATTGTGAATGCACCCAATCATGCAGGAATTCAG
GCTGGAGTTGACAGGTTTTATCGAACTTGTAAGCTGCTCGGAATCAATATGAGTAAGAAA
AAGTCTTACATAAACAGAACAGGTACATTTGAATTCACTAGCTTTTTCTATCGTTATGGG
TTTGTTGCCAATTTCAGCATGGAGCTTCCCAGTTTTGGGGTGTCTGGGATCAACGAGTCT
GCAGATATGAGTATTGGGGTCACTGTCATCAAAAACAATATGATAAACAATGATCTTGGT
CCAGCAACCGCTCAAATGGCCCTTCAGTTATTCATCAAAGATTACAGGTACACGTATCGG
TGCCACAGAGGTGACACACAAATACAAACCCGAAGATCATTTGAAATAAAGAAACTGTGG
GAGCAAACCCGTTCCAAAGCTGGGCTGCTGGTCTCCGATGGAGGTCCTAACTTATATAAC
ATTAGAAATCTCCACACCCCTGAAGTCTGTTTGAAATGGGAATTGATGGATGAGGATTAC
CAGGGGCGTTTATGCAACCCATTGAACCCATTTGTCAGTCATAAAGAGATTGAATCAGTG
AACAATGCAGTGATGATGCCGGCACATGGTCCAGCCAAAAACATGGAGTATGATGCTGTA
GCAACAACACACTCCTGGGTCCCCAAAAGAAATCGATCCATCTTGAATACTAGTCAAAGG
GGAATACTTGAAGATGAACAAATGTATCAAAGGTGCTGCAATTTATTTGAAAGGTTCTTC
CCCAGCAGTTCATACAGAAGGCCAGTCGGAATATCCAGTATGGTGGAGGCTATGGTTTCC
AGAGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAGGATTTC
ACTGAGATCATGAAGATCTGTTCCACCATTGAAGAACTCAGACGGCAAAAATAG

# Drug_Target_4_General_Function:
Involved in RNA-directed RNA polymerase activity

# Drug_Target_4_General_References:
2795713	Kawaoka Y, Krauss S, Webster RG: Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol. 1989 Nov;63(11):4603-8.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
311

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
86536

# Drug_Target_4_Name:
RNA-directed RNA polymerase catalytic subunit

# Drug_Target_4_Number_of_Residues:
757

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00602	Flu_PB1

# Drug_Target_4_Protein_Sequence:
>RNA-directed RNA polymerase catalytic subunit
MDVNPTLLFLKVPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRTHQYSERGRWTKNTE
TGAPQLNPIDGPLPEDNEPSGYAQTDCVLEAMAFLEESHPGIFENSCIETMEVVQQTRVD
KLTQGRQTYDWTLNRNQPAATALANTIEVFRSNGLMANESGRLIDFLKDVMESMDKEEIE
ITTHFQRKRRVRDNVTKKMVTQRTIGKKKQRLNKRSYLIRALTLNTMTKDAERGKLKRRA
IATPGMQIRGFVYFVETLARSICEKLEQSGLPVGGNEKKAKLANVVRKMMTNSQDTEISF
TITGDNTKWNENQNPRMFLAVITYITRNQPEWFRNILSIAPIMFSNKMARLGKGYMFESK
SMKLRTQISAEMLANIDLKYFNDSTRKKIEKIRPLLIDGTASLSPGMMMGMFNMLSTVLG
VSILNLGQKRYTKTTYWWDGLQSSDDFALIVNAPNHAGIQAGVDRFYRTCKLLGINMSKK
KSYINRTGTFEFTSFFYRYGFVANFSMELPSFGVSGINESADMSIGVTVIKNNMINNDLG
PATAQMALQLFIKDYRYTYRCHRGDTQIQTRRSFEIKKLWEQTRSKAGLLVSDGGPNLYN
IRNLHTPEVCLKWELMDEDYQGRLCNPLNPFVSHKEIESVNNAVMMPAHGPAKNMEYDAV
ATTHSWVPKRNRSILNTSQRGILEDEQMYQRCCNLFERFFPSSSYRRPVGISSMVEAMVS
RARIDARIDFESGRIKKEDFTEIMKICSTIEELRRQK

# Drug_Target_4_Reaction:
nucleoside triphosphate + RNAn = diphosphate + RNAn+1

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
RNA-dependent RNA polymerase which is responsible for replication and transcription of virus segments. Binds the promoter sequence of the encapsidated viral RNA. Displays an endonuclease activity involved in cap-stealing. Cleaves cellular pre-mRNA to generate primers for viral transcription

# Drug_Target_4_SwissProt_ID:
P16502

# Drug_Target_4_SwissProt_Name:
RDRP_I56A0

# Drug_Target_4_Synonyms:
EC 2.7.7.48
PB1
Polymerase basic protein 1
RNA-directed RNA polymerase subunit P1

# Drug_Target_4_Theoretical_pI:
9.74

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
11907645	Crotty S, Cameron C, Andino R: Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med. 2002 Feb;80(2):86-95. Epub 2001 Dec 4.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17907286	Ren FY, Jin H, Piao XX, Piao FS: Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B. World J Gastroenterol. 2007 Nov 7;13(41):5440-5.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
Not Available

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
Not Available

# Drug_Target_5_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_5_General_Function:
Biological information storage and information transfer

# Drug_Target_5_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
874

# Drug_Target_5_Locus:
All loci

# Drug_Target_5_Molecular_Weight:
7656 (double strand)

# Drug_Target_5_Name:
DNA

# Drug_Target_5_Number_of_Residues:
0

# Drug_Target_5_PDB_ID:
1BNA

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
Not Available

# Drug_Target_5_Protein_Sequence:
Not Available

# Drug_Target_5_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_5_SwissProt_ID:
Not Available

# Drug_Target_5_SwissProt_Name:
Not Available

# Drug_Target_5_Synonyms:
Deoxyribonucleic acid

# Drug_Target_5_Theoretical_pI:
Not Available

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
NT5C2

# Drug_Target_6_GenBank_ID_Gene:
D38524

# Drug_Target_6_GenBank_ID_Protein:
633071

# Drug_Target_6_GeneCard_ID:
NT5C2

# Drug_Target_6_Gene_Name:
NT5C2

# Drug_Target_6_Gene_Sequence:
>1686 bp
ATGTCGACCTCCTGGAGTGATCGGTTACAGAATGCAGCAGATATGCCTGCTAACATGGAT
AAGCATGCCCTGAAAAAGTATCGTCGAGAAGCCTATCATCGGGTGTTTGTGAACCGAAGT
TTAGCAATGGAAAAGATAAAGTGTTTTGGTTTTGATATGGATTATACCCTTGCTGTGTAC
AAGTCCCCAGAGTATGAGTCCCTTGGTTTTGAGCTTACTGTGGAGAGATTAGTTTCTATT
GGCTATCCCCAGGAGTTGCTCAGCTTTGCTTATGATTCTACATTCCCTACCAGGGGACTT
GTCTTTGACACACTGTATGGAAATCTTTTGAAAGTCGATGCCTATGGAAACCTCTTGGTC
TGTGCACATGGATTTAACTTTATAAGGGGACCAGAAACTAGAGAACAGTATCCAAATAAA
TTTATCCAGCGAGATGATACTGAAAGATTTTACATTCTGAACACACTATTCAACCTACCA
GAGACCTACCTGTTGGCCTGCCTAGTAGATTTTTTTACTAATTGTCCCAGATATACCAGT
TGTGAAACAGGATTTAAAGATGGGGACCTCTTCATGTCCTACCGGAGTATGTTCCAGGAT
GTAAGAGATGCTGTTGACTGGGTTCATTACAAGGGCTCCCTTAAGGAAAAGACAGTTGAA
AATCTTGAGAAGTATGTAGTCAAAGATGGAAAACTGCCTTTGCTTCTGAGCCGGATGAAG
GAAGTAGGGAAAGTATTTCTTGCTACCAACAGTGACTATAAATATACAGATAAAATTATG
ACTTACCTGTTTGACTTCCCACATGGCCCCAAGCCTGGGAGCTCCCATCGACCATGGCAG
TCCTACTTTGACTTGATCTTGGTGGATGCACGGAAACCACTCTTTTTTGGAGAAGGCACA
GTACTGCGTCAGGTGGATACTAAAACTGGCAAGCTGAAAATTGGTACCTACACAGGGCCC
CTACAGCATGGTATCGTCTACTCAGGAGGTTCTTCTGATACGATCTGTGACCTGTTGGGA
GCCAAGGGAAAAGACATTTTGTATATTGGAGATCACATTTTTGGGGACATTTTAAAATCA
AAGAAACGGCAAGGGTGGCGAACTTTTTTGGTGATTCCTGAACTCGCACAGGAGCTACAT
GTCTGGACTGACAAGAGTTCACTTTTCGAAGAACTTCAGAGCTTGGATATTTTCTTGGCT
GAACTCTACAAGCATCTTGACAGCAGTAGCAATGAGCGTCCAGACATCAGTTCCATCCAG
AGACGTATTAAGAAAGTAACTCATGACATGGACATGTGCTATGGGATGATGGGAAGCCTG
TTTCGCAGTGGCTCCCGGCAGACCCTTTTTGCCAGTCAAGTGATGCGTTATGCTGACCTC
TATGCAGCATCTTTCATCAACCTGCTGTATTACCCTTTCAGCTACCTCTTCAGGGCTGCC
CATGTCTTGATGCCTCATGAATCAACGGTGGAGCACACACACGTAGATATCAATGAGATG
GAGTCTCCTCTTGCCACCCGGAACCGCACATCAGTGGATTTCAAAGACACTGACTACAAG
CGGCACCAGCTGACACGGTCAATTAGTGAGATTAAACCTCCCAACCTCTTCCCACTGGCC
CCCCAGGAAATTACACACTGCCATGACGAAGATGATGATGAAGAGGAGGAGGAGGAGGAA
GAATAA

# Drug_Target_6_General_Function:
Involved in 5'-nucleotidase activity

# Drug_Target_6_General_References:
7999131	Oka J, Matsumoto A, Hosokawa Y, Inoue S: Molecular cloning of human cytosolic purine 5'-nucleotidase. Biochem Biophys Res Commun. 1994 Nov 30;205(1):917-22.

# Drug_Target_6_HGNC_ID:
HGNC:8022

# Drug_Target_6_HPRD_ID:
02686

# Drug_Target_6_ID:
289

# Drug_Target_6_Locus:
10q24.32-q24.33

# Drug_Target_6_Molecular_Weight:
64970

# Drug_Target_6_Name:
Cytosolic purine 5'-nucleotidase

# Drug_Target_6_Number_of_Residues:
561

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF05761	5_nucleotid

# Drug_Target_6_Protein_Sequence:
>Cytosolic purine 5'-nucleotidase
MSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVY
KSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLV
CAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTS
CETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMK
EVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGT
VLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKS
KKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQ
RRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAA
HVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNLFPLA
PQEITHCHDEDDDEEEEEEEE

# Drug_Target_6_Reaction:
a 5'-ribonucleotide + H2O = a ribonucleoside + phosphate

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
May have a critical role in the maintenance of a constant composition of intracellular purine/pyrimidine nucleotides in cooperation with other nucleotidases. Preferentially hydrolyzes inosine 5-prime-monophosphate (IMP) and other purine nucleotides

# Drug_Target_6_SwissProt_ID:
P49902

# Drug_Target_6_SwissProt_Name:
5NTC_HUMAN

# Drug_Target_6_Synonyms:
5'-nucleotidase cytosolic II
EC 3.1.3.5

# Drug_Target_6_Theoretical_pI:
6.05

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Membrane
single-pass type II membrane protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
ENPP1

# Drug_Target_7_GenBank_ID_Gene:
M57736

# Drug_Target_7_GenBank_ID_Protein:
189650

# Drug_Target_7_GeneCard_ID:
ENPP1

# Drug_Target_7_Gene_Name:
ENPP1

# Drug_Target_7_Gene_Sequence:
>2778 bp
ATGGAGCGCGACGGCTGCGCGGGGGGCGGGAGCCGCGGCGGCGAGGGCGGGCGCGCTCCC
CGGGAGGGCCCGGCGGGGAACGGCCGCGATCGGGGCCGCAGCCACGCTGCCGAGGCGCCC
GGGGACCCGCAGGCGGCCGCGTCCTTGCTGGCCCCTATGGACGTGGGGGAGGAGCCGCTG
GAGAAGGCGGCGCGCGCCCGCACTGCCAAGGACCCCAACACCTATAAAGTACTCTCGCTG
GTATTGTCAGTATGTGTGTTAACAACAATACTTGGTTGTATATTTGGGTTGAAACCAAGC
TGTGCCAAAGAAGTTAAAAGTTGCAAAGGTCGCTGTTTCGAGAGAACATTTGGGAACTGT
CGCTGTGATGCTGCCTGTGTTGAGCTTGGAAACTGCTGTTTAGATTACCAGGAGACGTGC
ATAGAACCAGAACATATATGGACTTGCAACAAATTCAGGTGTGGTGAGAAAAGGTTGACC
AGAAGCCTCTGTGCCTGTTCAGATGACTGCAAGGACAAGGGCGACTGCTGCATCAACTAC
AGTTCTGTGTGTCAAGGTGAGAAAAGTTGGGTAGAAGAACCATGTGAGAGCATTAATGAG
CCACAGTGCCCAGCAGGGTTTGAAACGCCTCCTACCCTCTTATTTTCTTTGGATGGATTC
AGGGCAGAATATTTACACACTTGGGGTGGACTTCTTCCTGTTATTAGCAAACTAAAAAAA
TGTGGAACATATACTAAAAACATGAGACCGGTATATCCAACAAAAACTTTCCCCAATCAC
TACAGCATTGTCACCGGATTGTATCCAGAATCTCATGGCATAATCGACAATAAAATGTAT
GATCCCAAAATGAATGCTTCCTTTTCACTTAAAAGTAAAGAGAAATTTAATCCTGAGTGG
TACAAAGGAGAACCAATTTGGGTCACAGCTAAGTATCAAGGCCTCAAGTCTGGCACATTT
TTCTGGCCAGGATCAGATGTGGAAATTAACGGAATTTTCCCAGACATCTATAAAATGTAT
AATGGTTCAGTACCATTTGAAGAAAGGATTTTAGCTGTTCTTCAGTGGCTACAGCTTCCT
AAAGATGAAAGACCACACTTTTACACTCTGTATTTAGAAGAACCAGATTCTTCAGGTCAT
TCATATGGACCAGTCAGCAGTGAAGTCATCAAAGCCTTGCAGAGGGTTGATGGTATGGTT
GGTATGCTGATGGATGGTCTGAAAGAGCTGAACTTGCACAGATGCCTGAACCTCATCCTT
ATTTCAGATCATGGCATGGAACAAGGCAGTTGTAAGAAATACATATATCTGAATAAATAT
TTGGGGGATGTTAAAAATATTAAAGTTATCTATGGACCTGCAGCTCGATTGAGACCCTCT
GATGTCCCAGATAAATACTATTCATTTAACTATGAAGGCATTGCCCGAAATCTTTCTTGC
CGGGAACCAAACCAGCACTTCAAACCTTACCTGAAACATTTCTTACCTAAGCGTTTGCAC
TTTGCTAAGAGTGATAGAATTGAGCCCTTGACATTCTATTTGGACCCTCAGTGGCAACTT
GCATTGAATCCCTCAGAAAGGAAATATTGTGGAAGTGGATTTCATGGCTCTGACAATGTA
TTTTCAAATATGCAAGCCCTCTTTGTTGGCTATGGACCTGGATTCAAGCATGGCATTGAG
GCTGACACCTTTGAAAACATTGAAGTCTATAACTTAATGTGTGATTTACTGAATTTGACA
CCGGCTCCTAATAACGGAACTCATGGAAGTCTTAACCACCTTCTAAAGAATCCTGTTTAT
ACGCCAAAGCATCCCAAAGAAGTGCACCCCCTGGTACAGTGCCCCTTCACAAGAAACCCC
AGAGATAACCTTGGCTGCTCATGTAACCCTTCGATTTTGCCGATTGAGGATTTTCAAACA
CAGTTCAATCTGACTGTGGCAGAAGAGAAGATTATTAAGCATGAAACTTTACCCTATGGA
AGACCTAGAGTTCTCCAGAAGGAAAACACCATCTGTCTTCTTTCCCAGCACCAGTTTATG
AGTGGATACAGCCAAGACATCTTAATGCCCCTTTGGACATCCTATACCGTGGACAGAAAT
GACAGTTTCTCTACGGAAGACTTCTCCAACTGTCTGTACCAGGACTTTAGAATTCCTCTT
AGTCCTGTCCATAAATGTTCATTTTATAAAAATAACACCAAAGTGAGTTACGGGTTCCTC
TCCCCACCACAACTAAATAAAAATTCAAGTGGAATATATTCTGAAGCTTTGCTTACTACA
AATATAGTGCCAATGTACCAGAGTTTTCAAGTTATATGGCGCTACTTTCATGACACCCTA
CTGCGAAAGTATGCTGAAGAAAGAAATGGTGTCAATGTCGTCAGTGGTCCTGTGTTTGAC
TTTGATTATGATGGACGTTGTGATTCCTTAGAGAATCTGAGGCAAAAAAGAAGAGTCATC
CGTAACCAAGAAATTTTGATTCCAACTCACTTCTTTATTGTGCTAACAAGCTGTAAAGAT
ACATCTCAGACGCCTTTGCACTGTGAAAACCTAGACACCTTAGCTTTCATTTTGCCTCAC
AGGACTGATAACAGCGAGAGCTGTGTGCATGGGAAGCATGACTCCTCATGGGTTGAAGAA
TTGTTAATGTTACACAGAGCACGGATCACAGATGTTGAGCACATCACTGGACTCAGCTTC
TATCAACAAAGAAAAGAGCCAGTTTCAGACATTTTAAAGTTGAAAACACATTTGCCAACC
TTTAGCCAAGAAGACTGA

# Drug_Target_7_General_Function:
Involved in nucleic acid binding

# Drug_Target_7_General_References:
10453738	Nakamura I, Ikegawa S, Okawa A, Okuda S, Koshizuka Y, Kawaguchi H, Nakamura K, Koyama T, Goto S, Toguchida J, Matsushita M, Ochi T, Takaoka K, Nakamura Y: Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet. 1999 Jun;104(6):492-7.
10480624	Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, Ercolino T, Scarlato G, Iacoviello L, Vigneri R, Tassi V, Trischitta V: A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999 Sep;48(9):1881-4.
1315502	Funakoshi I, Kato H, Horie K, Yano T, Hori Y, Kobayashi H, Inoue T, Suzuki H, Fukui S, Tsukahara M, et al.: Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase. Arch Biochem Biophys. 1992 May 15;295(1):180-7.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
2211644	Buckley MF, Loveland KA, McKinstry WJ, Garson OM, Goding JW: Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J Biol Chem. 1990 Oct 15;265(29):17506-11.
7737162	Belli SI, Mercuri FA, Sali A, Goding JW: Autophosphorylation of PC-1 (alkaline phosphodiesterase I/nucleotide pyrophosphatase) and analysis of the active site. Eur J Biochem. 1995 Mar 15;228(3):669-76.
8001561	Belli SI, Goding JW: Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphodiesterase I and nucleotide pyrophosphatase activities. Eur J Biochem. 1994 Dec 1;226(2):433-43.

# Drug_Target_7_HGNC_ID:
HGNC:3356

# Drug_Target_7_HPRD_ID:
01415

# Drug_Target_7_ID:
508

# Drug_Target_7_Locus:
6q22-q23

# Drug_Target_7_Molecular_Weight:
104925

# Drug_Target_7_Name:
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1

# Drug_Target_7_Number_of_Residues:
925

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01033	Somatomedin_B
PF01663	Phosphodiest

# Drug_Target_7_Protein_Sequence:
>Ectonucleotide pyrophosphatase/phosphodiesterase 1
MERDGCAGGGSRGGEGGRAPREGPAGNGRDRGRSHAAEAPGDPQAAASLLAPMDVGEEPL
EKAARARTAKDPNTYKVLSLVLSVCVLTTILGCIFGLKPSCAKEVKSCKGRCFERTFGNC
RCDAACVELGNCCLDYQETCIEPEHIWTCNKFRCGEKRLTRSLCACSDDCKDKGDCCINY
SSVCQGEKSWVEEPCESINEPQCPAGFETPPTLLFSLDGFRAEYLHTWGGLLPVISKLKK
CGTYTKNMRPVYPTKTFPNHYSIVTGLYPESHGIIDNKMYDPKMNASFSLKSKEKFNPEW
YKGEPIWVTAKYQGLKSGTFFWPGSDVEINGIFPDIYKMYNGSVPFEERILAVLQWLQLP
KDERPHFYTLYLEEPDSSGHSYGPVSSEVIKALQRVDGMVGMLMDGLKELNLHRCLNLIL
ISDHGMEQGSCKKYIYLNKYLGDVKNIKVIYGPAARLRPSDVPDKYYSFNYEGIARNLSC
REPNQHFKPYLKHFLPKRLHFAKSDRIEPLTFYLDPQWQLALNPSERKYCGSGFHGSDNV
FSNMQALFVGYGPGFKHGIEADTFENIEVYNLMCDLLNLTPAPNNGTHGSLNHLLKNPVY
TPKHPKEVHPLVQCPFTRNPRDNLGCSCNPSILPIEDFQTQFNLTVAEEKIIKHETLPYG
RPRVLQKENTICLLSQHQFMSGYSQDILMPLWTSYTVDRNDSFSTEDFSNCLYQDFRIPL
SPVHKCSFYKNNTKVSYGFLSPPQLNKNSSGIYSEALLTTNIVPMYQSFQVIWRYFHDTL
LRKYAEERNGVNVVSGPVFDFDYDGRCDSLENLRQKRRVIRNQEILIPTHFFIVLTSCKD
TSQTPLHCENLDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHRARITDVEHITGLSF
YQQRKEPVSDILKLKTHLPTFSQED

# Drug_Target_7_Reaction:
Hydrolytically removes 5'-nucleotides successively from the 3'-hydroxy termini of 3'-hydroxy-terminated oligonucleotides

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Has a broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. Can hydrolyze nucleoside 5' triphosphates such as ATP, GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate. Can hydrolyze diadenosine polyphosphates and 3',5'-cAMP to AMP. It may play a role in the regulation of pyrophosphate production, the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling

# Drug_Target_7_SwissProt_ID:
P22413

# Drug_Target_7_SwissProt_Name:
ENPP1_HUMAN

# Drug_Target_7_Synonyms:
E- NPP 1
EC 3.1.4.1
EC 3.6.1.9
Nucleotide pyrophosphatase
Phosphodiesterase I/nucleotide pyrophosphatase 1
Plasma-cell membrane glycoprotein PC-1

# Drug_Target_7_Theoretical_pI:
7.14

# Drug_Target_7_Transmembrane_Regions:
77-97

#END_DRUGCARD DB00811
